NYSE:ABT - Abbott Laboratories Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $71.42 +0.90 (+1.28 %) (As of 01/18/2019 04:00 PM ET)Previous Close$70.52Today's Range$70.78 - $71.7452-Week Range$55.58 - $74.92Volume8.49 million shsAverage Volume7.02 million shsMarket Capitalization$122.63 billionP/E Ratio28.57Dividend Yield1.83%Beta1.24 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; benchtop systems and rapid tests in the areas of infectious diseases; molecular point-of-care test systems for influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois. Receive ABT News and Ratings via Email Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:ABT Previous Symbol CUSIP00282410 Webwww.abbott.com Phone224-667-6100Debt Debt-to-Equity Ratio0.62 Current Ratio1.42 Quick Ratio1.13Price-To-Earnings Trailing P/E Ratio28.57 Forward P/E Ratio24.71 P/E Growth1.87 Sales & Book Value Annual Sales$27.39 billion Price / Sales4.58 Cash Flow$4.8985 per share Price / Cash Flow14.58 Book Value$17.87 per share Price / Book4.00Profitability EPS (Most Recent Fiscal Year)$2.50 Net Income$477 million Net Margins2.91% Return on Equity16.05% Return on Assets6.95%Miscellaneous Employees99,000 Outstanding Shares1,756,330,000Market Cap$122.63 billion OptionableOptionable Abbott Laboratories (NYSE:ABT) Frequently Asked Questions What is Abbott Laboratories' stock symbol? Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT." How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories? Abbott Laboratories announced a quarterly dividend on Friday, December 14th. Investors of record on Tuesday, January 15th will be given a dividend of $0.32 per share on Friday, February 15th. This represents a $1.28 annualized dividend and a dividend yield of 1.79%. The ex-dividend date of this dividend is Monday, January 14th. This is a positive change from Abbott Laboratories's previous quarterly dividend of $0.28. View Abbott Laboratories' Dividend History. How were Abbott Laboratories' earnings last quarter? Abbott Laboratories (NYSE:ABT) released its quarterly earnings data on Wednesday, October, 17th. The healthcare product maker reported $0.75 EPS for the quarter, meeting the Thomson Reuters' consensus estimate of $0.75. The healthcare product maker had revenue of $7.66 billion for the quarter, compared to analysts' expectations of $7.65 billion. Abbott Laboratories had a net margin of 2.91% and a return on equity of 16.05%. The firm's revenue for the quarter was up 12.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.66 earnings per share. View Abbott Laboratories' Earnings History. When is Abbott Laboratories' next earnings date? Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, January 23rd 2019. View Earnings Estimates for Abbott Laboratories. How can I listen to Abbott Laboratories' earnings call? Abbott Laboratories will be holding an earnings conference call on Wednesday, January 23rd at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link. What price target have analysts set for ABT? 21 analysts have issued twelve-month target prices for Abbott Laboratories' stock. Their forecasts range from $68.00 to $86.00. On average, they expect Abbott Laboratories' share price to reach $76.8474 in the next twelve months. This suggests a possible upside of 7.6% from the stock's current price. View Analyst Price Targets for Abbott Laboratories. What is the consensus analysts' recommendation for Abbott Laboratories? 21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 1 sell rating, 3 hold ratings and 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories. Has Abbott Laboratories been receiving favorable news coverage? Headlines about ABT stock have trended positive on Friday, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Abbott Laboratories earned a news impact score of 2.8 on InfoTrie's scale. They also assigned press coverage about the healthcare product maker a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. Who are some of Abbott Laboratories' key competitors? Some companies that are related to Abbott Laboratories include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG) and Shire (SHPG). Who are Abbott Laboratories' key executives? Abbott Laboratories' management team includes the folowing people: Mr. Miles D. White, Chairman & CEO (Age 64)Mr. Robert B. Ford, Pres & COO (Age 45)Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 49)Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 53)Mr. Daniel Gesua Sive Salvadori, Exec. VP of Nutritional Products (Age 40) Who are Abbott Laboratories' major shareholders? Abbott Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Atalanta Sosnoff Capital LLC (0.06%), Gateway Investment Advisers LLC (0.06%), Nisa Investment Advisors LLC (0.05%), Retirement Systems of Alabama (0.05%), Park National Corp OH (0.03%) and Gofen & Glossberg LLC IL (0.03%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Andrew H Lane, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Pederson, Michael J Warmuth, Miles D White, Robert E Funck, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories. Which institutional investors are selling Abbott Laboratories stock? ABT stock was sold by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Sit Investment Associates Inc., Dalton Greiner Hartman Maher & Co., Gulf International Bank UK Ltd, Gradient Investments LLC, Stralem & Co. Inc., Prentiss Smith & Co. Inc. and Nisa Investment Advisors LLC. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrew H Lane, Brian J Blaser, Daniel Gesua Sive Salvadori, Jaime Contreras, Jared Watkin, Michael J Pederson, Miles D White, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories. Which institutional investors are buying Abbott Laboratories stock? ABT stock was bought by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Patten & Patten Inc. TN, Centre Asset Management LLC, Town & Country Bank & Trust CO dba First Bankers Trust CO, Cullinan Associates Inc., Nachman Norwood & Parrott Inc, MinichMacGregor Wealth Management LLC and Granite Investment Advisors LLC. View Insider Buying and Selling for Abbott Laboratories. How do I buy shares of Abbott Laboratories? Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Abbott Laboratories' stock price today? One share of ABT stock can currently be purchased for approximately $71.42. How big of a company is Abbott Laboratories? Abbott Laboratories has a market capitalization of $122.63 billion and generates $27.39 billion in revenue each year. The healthcare product maker earns $477 million in net income (profit) each year or $2.50 on an earnings per share basis. Abbott Laboratories employs 99,000 workers across the globe. What is Abbott Laboratories' official website? The official website for Abbott Laboratories is http://www.abbott.com. How can I contact Abbott Laboratories? Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100. MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 715 (Vote Outperform)Underperform Votes: 576 (Vote Underperform)Total Votes: 1,291MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/18/2019 by MarketBeat.com StaffFeatured Article: What is the Dividend Aristocrat Index?